Search | Clinical Trials Finder

Conditions: Healthy
Interventions: Transderm Scop®, Intravenous scopolamine hydrobromide; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 27
States / cities: Tucson, Arizona • Riverside, California • San Diego, California + 24 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo, Tiotropium, Olodaterol, Tiotropium + Olodaterol, Respimat; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 8
States / cities: Torrance, California • Hartford, Connecticut • Livonia, Michigan + 5 more

Conditions: Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
Interventions: Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 2,059 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 221
States / cities: Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium, ipratropium bromide / albuterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 10
States / cities: Phoenix, Arizona • Lakewood, California • Sepulveda, California + 7 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium Bromide, Fluticasone Propionate/Salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 99 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 35
States / cities: Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg), Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg, Tiotropium 18 μg (TIO 18 μg), Placebo to TIO 18 μg; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 85
States / cities: Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol, Placebo to tiotropium; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 25
States / cities: Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 22 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: QVA149, NVA237, tiotropium, Salbutamol/albuterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 2,224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 53
States / cities: Birmingham, Alabama • Fairhope, Alabama • Florence, Alabama + 46 more

Conditions: Asthma
Interventions: tiotropium 5mcg/day, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 18
States / cities: Fountain Valley, California • Fresno, California • Stockton, California + 15 more

Conditions: Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 25
States / cities: Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more

Conditions: COPD, Chronic Obstructive Pulmonary Disease
Interventions: CHF 5259, Placebo, Tiotropium Bromide 18 µg Inhalation Capsule; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 40 Years and older
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 112
States / cities: Birmingham, Alabama • Dothan, Alabama • Montgomery, Alabama + 99 more

Conditions: Motion Sickness
Interventions: DPI-386 Nasal Gel, DPI-386 Placebo Nasal Gel, Transderm Scop®; Drug
Lead sponsor: Repurposed Therapeutics, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Asthma
Interventions: tiotropium bromide, salmeterol xinafoate, beclomethasone dipropionate; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Denver, Colorado + 7 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 23 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium, Olodaterol, Fluticasone propionate, Salmeterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 45
States / cities: Jasper, Alabama • Flagstaff, Arizona • Fullerton, California + 40 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®); Drug
Lead sponsor: Lupin, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 34
States / cities: Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more

Conditions: Motion Sickness
Interventions: scopolamine HBr, Transdermal Scopolamine; Drug
Lead sponsor: Repurposed Therapeutics, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
Interventions: Revefenacin, Spiriva Handihaler®, Placebo for Revefenacin, Placebo for Spiriva Handihaler®; Drug · Combination Product
Lead sponsor: Mylan Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Rock Hill, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149), tiotropium, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 2,144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: SUN-101 50 mcg BID eFlow (CS) nebulizer, Spiriva® 18 mcg QD Handihaler; Drug
Lead sponsor: Sunovion Respiratory Development Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 1,087 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 83
States / cities: Andalusia, Alabama • Birmingham, Alabama • Jasper, Alabama + 68 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium + olodaterol, tiotropium, olodaterol, Placebo, Respimat; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Jasper, Alabama • Easley, South Carolina • Greenville, South Carolina + 1 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BI 1744 CL plus tiotropium bromide, Respimat® Inhaler; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 5
States / cities: Clearwater, Florida • Tampa, Florida • Philadelphia, Pennsylvania + 2 more

Search by objective public record fields.

Scopolamine Patch Pharmacokinetics in Healthy Adults

Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)